Has Michael Herman, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,904 in general payments to Michael Herman, MD across 20 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Herman, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Herman, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Herman, MD

Radiation Oncology · Round Rock, TXNPI 1134419955

Payments from drug & device makers

$3,904in general payments, 2019–2025

Across 20 payments — averaging $195.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$2K
Elekta, Inc.$802
Raysearch Laboratories AB (publ)$485
Medtronic$148
Johnson & Johnson$107
Boston Scientific$96
plus $65 from 1 others

What the payments were for

Consulting fees$2,20056%
Food & beverage$1,70444%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	1	$2,200
Elekta, Inc.	7	$802
Raysearch Laboratories AB (publ)	1	$485
Medtronic	2	$148
Johnson & Johnson	6	$107
Boston Scientific	2	$96
Siemens Medical Solutions USA, Inc.	1	$65

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,904 in reported general payments places this provider in the 75th percentile of 418 radiation oncology providers in Texas.

See all radiation oncology providers in Texas →

Medicare billing

Part B allowed, 2024

$3,167,076

Medicare patients

458

Services billed

30,798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Mometasone Furoate	42	$730
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	29	$661
Ondansetron OdtOndansetron	18	$210
SsdSilver Sulfadiazine	11	$183
Prochlorperazine Maleate	18	$153
Silver Sulfadiazine	14	$91
Ondansetron Hcl	15	$90
Levothyroxine Sodium	12	$54

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Round Rock

Charles HsuRound Rock$364K
Daniel GomezHouston$8.7M
Neil DesaiDallas$8.6M
Chad TangHouston$7.7M
James WelshHouston$5.1M
Caroline ChungHouston$3.7M
Karen HoffmanHouston$2.6M
Clifton FullerHouston$1.6M
Robert TimmermanDallas$1.5M
Steven LinHouston$1.5M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →